Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Barinthus Biotherapeutics plc - American Depositary Shares (NQ:BRNS)

1.290 -0.040 (-3.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Barinthus Biotherapeutics plc - American Depositary Shares

< Previous 1 2 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates DAY, BRNS, ETNB, VRNT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECO, BRNS, VRNT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
From Kahn Swick & Foti, LLC
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics
Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own. 
Via Stocktwits
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
US Stocks Mixed; Bank of America Earnings Top Views
 
Via Benzinga
Q2 Virtual Investor Summit: Presentations Available Now
Via ACCESS Newswire
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
Via ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Via ACCESS Newswire
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
From Barinthus Biotherapeutics
Via GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.